Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recommendations for pharmacotranscriptomic profiling of drug response in CNS disorders.
Xicota L, De Toma I, Maffioletti E, Pisanu C, Squassina A, Baune BT, Potier MC, Stacey D, Dierssen M; European College of Neuropsychopharmacology (ECNP) Pharmacogenomics & Transcriptomics Thematic Workgroup. Xicota L, et al. Among authors: dierssen m. Eur Neuropsychopharmacol. 2022 Jan;54:41-53. doi: 10.1016/j.euroneuro.2021.10.005. Epub 2021 Nov 4. Eur Neuropsychopharmacol. 2022. PMID: 34743061 Review.
Semantic Verbal Fluency Pattern, Dementia Rating Scores and Adaptive Behavior Correlate With Plasma Aβ42 Concentrations in Down Syndrome Young Adults.
Hoyo LD, Xicota L, Sánchez-Benavides G, Cuenca-Royo A, de Sola S, Langohr K, Fagundo AB, Farré M, Dierssen M, de la Torre R. Hoyo LD, et al. Among authors: dierssen m. Front Behav Neurosci. 2015 Nov 18;9:301. doi: 10.3389/fnbeh.2015.00301. eCollection 2015. Front Behav Neurosci. 2015. PMID: 26635555 Free PMC article.
Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial.
de la Torre R, de Sola S, Hernandez G, Farré M, Pujol J, Rodriguez J, Espadaler JM, Langohr K, Cuenca-Royo A, Principe A, Xicota L, Janel N, Catuara-Solarz S, Sanchez-Benavides G, Bléhaut H, Dueñas-Espín I, Del Hoyo L, Benejam B, Blanco-Hinojo L, Videla S, Fitó M, Delabar JM, Dierssen M; TESDAD study group. de la Torre R, et al. Among authors: dierssen m. Lancet Neurol. 2016 Jul;15(8):801-810. doi: 10.1016/S1474-4422(16)30034-5. Lancet Neurol. 2016. PMID: 27302362 Clinical Trial.
Translating molecular advances in Down syndrome and Fragile X syndrome into therapies.
Faundez V, De Toma I, Bardoni B, Bartesaghi R, Nizetic D, de la Torre R, Cohen Kadosh R, Herault Y, Dierssen M, Potier MC; Down Syndrome and Other Genetic Developmental Disorders ECNP Network. Faundez V, et al. Among authors: dierssen m. Eur Neuropsychopharmacol. 2018 Jun;28(6):675-690. doi: 10.1016/j.euroneuro.2018.03.006. Epub 2018 Jun 7. Eur Neuropsychopharmacol. 2018. PMID: 29887288 Review.
Metabolomics predicts the pharmacological profile of new psychoactive substances.
Olesti E, De Toma I, Ramaekers JG, Brunt TM, Carbó ML, Fernández-Avilés C, Robledo P, Farré M, Dierssen M, Pozo ÓJ, de la Torre R. Olesti E, et al. Among authors: dierssen m. J Psychopharmacol. 2019 Mar;33(3):347-354. doi: 10.1177/0269881118812103. Epub 2018 Nov 19. J Psychopharmacol. 2019. PMID: 30451567
225 results